Skip to content
Business Times – Lifestyle
Author:
Replimune, Inc.
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
June 26, 2026
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 29, 2026